clinical development and clinical use those targeting T cell inhibitor receptors, referred to as “checkpoints”, are the most advanced. They include monoclonal antibodies directed against cytotoxic T-lymphocyte antigen…
Immune checkpoints constitute a distinctive set of proteins that belong to the B7 family. The engagement of these transmembrane receptors with their ligands provides critical signals to inhibit T-cell ... interactions…
with B10G5 also enhanced the efficacy of other cancer immunotherapeutic modalities, such as immune checkpoint blockade or adoptive cell-based therapy pre-clinically. Our study has launched a new avenue
With their ground-breaking clinical success, immune checkpoint inhibitors (ICIs) have opened a new chapter in cancer treatment; however, not all patients have a response to ICI treatment. Current approaches…
also express other receptors that inhibit their proliferation and cytokine production, known as immune checkpoints. Among these receptors are Cytotoxic T Lymphocyte Antigen-4 (CTLA-4), programmed death
stimulate the immune system to destroy tumor cells. Immunotherapy includes medications that target immune checkpoints. Immune checkpoint inhibitors are specific antibodies that target immune checkpoints. In this…
Paediatric Strategy Forum organised by ACCELERATE and the European Medicines Agency concentrated on vulnerable checkpoint impediments for use in combination remedy in children and adolescents. As vulnerable checkpoint…
Checkpoint inhibitors have revolutionized the field of oncology by harnessing the power of the immune system to combat cancer. These agents, such as Programmed Cell death Protein ... evade immune recognition and…
Sarcoid Like Reactions (DISR) have recently been described as a potential consequence of immune checkpoint inhibitor therapy. However, hypercalcemia associated with DISR has not been reported. Clinical case ... node…
Checkpoint inhibitor immunotherapy has significantly advanced treatment of a growing number of advanced malignancies. A consequences of immune system activation that leads to tumor cell destruction by checkpoint…
Background: Targeting the immune checkpoints cytotoxic T-lymphocyteassociated protein 4 (CTLA-4) and programmed death 1 (PD-1) with inhibitory antibodies has demonstrated effective and durable antitumor activity in…
Lung cancer is the top common cancer and cause of cancer-related death worldwide. Checkpoint blockade immunotherapies have shown extraordinarily anti-tumor effects, but only benefit the minority of patients ... Purpose…
have briefly reviewed the molecular mechanism involved in DNA damage and repair at various checkpoints of the cell cycle in eukaryotic cells. Eukaryotic cells have an ability to develop ... results in cell cycle arrest…
Endocrine complications arising from the use of immune checkpoint inhibitors present unique challenges in oncology and require specialized diagnostic and management strategies. This article provides a comprehensive…
Immune checkpoint inhibitors have revolutionized the landscape of cancer treatment by leveraging the body’s own immune system to fight cancer cells. This review article delves into the mechanisms ... immune checkpoints…
Cancer immunotherapy has revolutionized the treatment landscape, with Immune Checkpoint Inhibitors (ICIs) playing a pivotal role in harnessing the body's immune system to combat cancer. However, not all patients…
tumor immunity. Patients with CLL are clear candidates for novel immunotherapies, such as immune checkpoint blockade, that try to restore the patients’ immune activity to induce therapeutic responses. Nonetheless…
immune responses to tumors. Siglecs are mostly inhibitory receptors similar to known immune checkpoints including PD-1 or CTLA-4 that are successfully targeted with blocking antibodies for cancer immunotherapy ... next…
immune responses to tumors. Siglecs are mostly inhibitory receptors similar to known immune checkpoints including PD-1 or CTLA-4 that are successfully targeted with blocking antibodies for cancer immunotherapy ... next…
Programmed cell death protein 1 (PD-1) and PD-L1 function as major immune checkpoint regulators, which are the inhibitory pathways in the immune system that maintain self–tolerance ... modulate the immune response. The…
cell mediated responses are controlled by checkpoints that limit over-activation of effector cells and excessive pathology. However, over control of the checkpoints will lead to weak immune responses ... known about the…
Purpose: Antibodies that target immune checkpoint molecules have demonstrated significant and durable clinical benefit through re-activation and proliferation of pre-existing tumor-infiltrating CD8+ T cells in a broad…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.